Pavmed Sustainability Profile
Pavmed Inc., a pioneering medical technology company headquartered in the United States, was founded in 2014. The company focuses on developing innovative solutions across various medical fields, including gastroenterology, urology, and general surgery. With a commitment to enhancing patient care, Pavmed has introduced unique products such as the EsoGuard® and the CarpX® device, which stand out for their advanced design and efficacy. Operating primarily in the US, Pavmed has achieved significant milestones, including successful clinical trials and regulatory approvals that underscore its market position. The company is dedicated to addressing unmet medical needs, making it a notable player in the medical device industry. With a strong emphasis on innovation and patient outcomes, Pavmed continues to shape the future of healthcare technology.
DitchCarbon Score
How does Pavmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pavmed's score of 25 is lower than 59% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pavmed's reported carbon emissions
In 2023, Pavmed Inc. reported total carbon emissions of approximately 115,790 kg CO2e, comprising 65,440 kg CO2e from Scope 1 emissions and 50,350 kg CO2e from Scope 2 emissions. This data reflects the company's operational footprint within the US. In comparison, the previous year's emissions in 2022 were about 97,620 kg CO2e, with 61,200 kg CO2e from Scope 1 and 36,420 kg CO2e from Scope 2. Pavmed has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests that while the company is aware of its emissions, it has yet to formalise a strategy for significant reductions or align with frameworks such as the Science Based Targets initiative (SBTi). Overall, Pavmed's emissions data indicates a commitment to transparency, but further action may be necessary to enhance their climate strategy and achieve meaningful reductions in their carbon footprint.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | 611,839,000 |
| Scope 2 | 241,103,000 |
| Scope 3 | - |
How Carbon Intensive is Pavmed's Industry?
How Carbon Intensive is Pavmed's Location?
Pavmed's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pavmed has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
